NCT06589596
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
At risk: Primary completion moved at least 11 months later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 31 versions: 28 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Sep 30, 2027 to Aug 31, 2028 Show 7 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 42 words
- Enrollment increased: 525 → 695 participants
- Interventions modified
- Trial arms changed: 4 → 6
- Secondary endpoints: details revised at 3 of 14 entries
- Study description expanded, about 224 words
- Minor Trial sites expanded: 98 → 101 locationsv30
- Minor Study sites: 96 to 98v29
- Minor Trial sites expanded: 92 → 96 locationsv28
- Minor Trial sites expanded: 87 → 92 locationsv27
- Minor Trial sites expanded: 82 → 87 locationsv26
- Minor Study sites: 80 to 82v25
Notable Enrollment increased: 244 → 525 participantsv24 Show 5 more changesShow less
- Primary endpoint(s) modified
- Primary and study completion moved earlier from Jan 2029 to Sep 30, 2027
- Start date: Oct 11, 2024 to Jan 10, 2025
- Trial sites expanded: 62 → 80 locations
- Study description expanded, about 1 word
- Minor Study sites: 59 to 62v23
- Minor Study sites: 47 to 59v22
- Minor Site details revised at 1 of 47 sitesv21
- Minor Study sites: 45 to 47v20
- Minor Study sites: 44 to 45v19
Notable Lead sponsor: BeiGene to BeOne Medicinesv17 Show 5 more changesShow less
- Primary and study completion dates: Jun 2027 to Jan 2029
- Eligibility criteria expanded, about 29 words
- Enrollment target: 237 to 244
- Study sites: 41 to 44
- Study description expanded, about 36 words
- Minor Study sites: 36 to 41v16
- Minor Study sites: 45 to 36v15
Notable Enrollment target: 92 to 237v12 Show 9 more changesShow less
- Primary and study completion dates: Nov 2026 to Jun 2027
- Eligibility criteria expanded, about 73 words
- Primary endpoints: 5 to 6
- Interventions: BGB-58067 (Drug) to BG-89894 (Drug), BGB-58067 (Drug), Standard of Care Therapy (Drug)
- Secondary endpoints revised (14)
- Study description expanded, about 11 words
- Study sites revised (45)
- Study title expanded, about 10 words
- Study arms: 2 to 4
- Minor Site details revised at 3 of 45 sitesv11
- Minor Study sites: 37 to 45v10
- Minor Study sites: 32 to 37v9
- Minor Site details revised at 3 of 32 sitesv8
- Minor Study sites: 30 to 32v7
- Minor Site details revised at 4 of 30 sitesv6
- Minor Site details revised at 1 of 30 sitesv5
- Minor Site details revised at 6 of 30 sitesv4
- Minor Study sites: 1 to 30v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria revised
- Study sites: 0 to 1
- Start date changed from estimate of Oct 2024 to Oct 11, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (14)
Show 9 moreShow less
Arms and interventions
Sequential cohorts of increasing dose levels of BGB-58067 as monotherapy will be evaluated.
Sequential cohorts of increasing dose levels of BGB-58067 in combination with BG-89894 will be evaluated. Enrollment in this combination has been discontinued.
Sequential cohorts of increasing dose levels of BGB-58067 in combination with standard of care therapy will be evaluated.
Recommended Dose(s) for Expansion (RDFE\[s\]) of BGB-58067 alone will be evaluated for selected indications and regimen(s) based on emerging data.
RDFE(s) of BGB-58067 in combination with standard of care therapy will be evaluated for selected indications and regimen(s) based on emerging data.
RDFE(s) of BGB-58067 in combination with novel anticancer therapies will be evaluated for selected indications and regimen(s) based on emerging data.
Drugs: BGB-58067, BG-89894, Standard of Care Therapy, RAS(ON) Inhibitors
Sites
101 sites in 11 countries
China 47, United States 12, Brazil 10, South Korea 6, Australia 5, France 5, Malaysia 5, Thailand 5, Spain 4, Denmark 1, Moldova 1